Waltham, MA – According to filings with the U.S. Securities and Exchange Commission, Invivyd is raising $23,749,998.00 in new funding. Sources indicate as part of senior management Director, Tamsin Berry played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Invivyd
Invivyd is a biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases. We are developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. Our technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify high-quality, long-lasting antibodies with a high barrier to viral escape. Our products can be tuned to optimize across potency, breadth of neutralization, and half-life and can be developed for use in both prevention and treatment of disease. Our goal is to change the paradigm for combatting viral infection by delivering rapid and lasting antibody immunity to protect the general public and ensure vulnerable populations are never left behind.

To learn more about Invivyd, visit http://www.invivyd.com/

Contact:
Tamsin Berry, Director
781-819-0080

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved